INTRODUCTION AND OBJECTIVES: Identifying effective treatments for castration-resistant prostate cancer (CRPC) is important to prevent its persistent progression following androgen deprivation therapy. In a previous study, we showed that changes in the expression of genes concerned with oxidative stress regulation induced carcinogenesis and castration-resistant growth in prostate cancer. Herein, we investigated the chemotherapeutic potential of luteolin, an anti-oxidative flavonoid, on prostate cancer and CRPC.
METHODS: Male transgenic rats for adenocarcinoma of prostate (TRAP) were divided into three groups (n ¼ 12 in each group) and fed the following for 8 weeks: basal diet, diet containing 20 ppm luteolin, and diet containing 100 ppm luteolin. Prostate tissues were collected from each animal for histopathological, gene, and protein expression analysis. PCai cells established from the TRAP prostate tumor and 22Rv1 cells were subcutaneously implanted in castrated and non-castrated nude mice, and in vivo tumor growth was analyzed. Subsequently, the effect of luteolin on cell proliferation and apoptosis in PCai1 and 22Rv1 cells was analyzed.
RESULTS: Luteolin decreased the incidence of adenocarcinoma and suppressed its progression from PIN to adenocarcinoma in TRAP. An increased apoptosis index with activation of caspase-3 and 7 was observed with high grade-PIN in the luteolin-fed TRAP. Production of reactive oxygen species and mRNA expression of the oxidative stress defense genes Gpx2 and Ho-1 were reduced by luteolin. Furthermore, luteolin inhibited tumor growth in the xenograft model via apoptosis induction and Gpx2 down-regulation. Luteolin also suppressed PCai1 and 22Rv1 cell proliferation in a dose-dependent manner in vitro by caspase-3 and 7-dependent apoptosis.
CONCLUSIONS: Luteolin decreased cell proliferation in a dose-dependent manner, and induced apoptosis with caspase activation in both, PCai1 and 22Rv1 cells. Dietary luteolin also suppressed tumor growth by increasing apoptosis and inhibiting angiogenesis in the PCai1 xenograft model. These results suggest that luteolin is a potential therapeutic agent for CRPC.
